161 related articles for article (PubMed ID: 31594365)
1. Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment.
McFarlane T; Rehman N; Wang K; Lee J; Carter C
Ann Palliat Med; 2020 May; 9(3):1296-1306. PubMed ID: 31594365
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
4. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Boruah PK; Bolesta S; Shetty SM
Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
[TBL] [Abstract][Full Text] [Related]
5. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
Schneider JA; Cohen PR
Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
[TBL] [Abstract][Full Text] [Related]
6. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
7. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions and organ damage: The skin.
Marzano AV; Borghi A; Cugno M
Eur J Intern Med; 2016 Mar; 28():17-24. PubMed ID: 26674736
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
Viale PH
Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
[TBL] [Abstract][Full Text] [Related]
10. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
11. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous reactions to chemotherapy and their management.
Wyatt AJ; Leonard GD; Sachs DL
Am J Clin Dermatol; 2006; 7(1):45-63. PubMed ID: 16489842
[TBL] [Abstract][Full Text] [Related]
13. Non-rash dermatologic adverse events related to targeted therapies.
Bryce J; Boers-Doets CB
Semin Oncol Nurs; 2014 Aug; 30(3):155-68. PubMed ID: 25085027
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.
Power WJ; Ghoraishi M; Merayo-Lloves J; Neves RA; Foster CS
Ophthalmology; 1995 Nov; 102(11):1669-76. PubMed ID: 9098260
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
16. What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care.
Anders CK; LeBoeuf NR; Bashoura L; Faiz SA; Shariff AI; Thomas A
Am Soc Clin Oncol Educ Book; 2020 May; 40():55-70. PubMed ID: 32421449
[TBL] [Abstract][Full Text] [Related]
17. [Stevens-Johnson syndrome and Hodgkin's disease: A fortuitous association or paraneoplastic syndrome?].
Schoeffler A; Levy E; Weinborn M; Cuny JF; Schmutz JL; Barbaud A; Cribier B; Bursztejn AC
Ann Dermatol Venereol; 2014 Feb; 141(2):134-40. PubMed ID: 24507208
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
[TBL] [Abstract][Full Text] [Related]
19. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
[TBL] [Abstract][Full Text] [Related]
20. Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China.
Sun J; Liu J; Gong QL; Ding GZ; Ma LW; Zhang LC; Lu Y
Drug Des Devel Ther; 2014; 8():2539-47. PubMed ID: 25548516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
